The therapeutic potential of depalmitoylation inhibition was further validated by Zhou et al.; hydroxychloroquine (HCQ), a PPT1 inhibitor, enhanced AEG-1 palmitoylation, subsequently inhibiting cell growth in HCC [33]. This evidence concerns the gene PPT1 and hepatocellular carcinoma.